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Biomaterial-based scaffolds are promising tools for controlled immunomodulation. They
can be applied as three dimensional (3D) culture systems in vitro, whereas in vivo
they may be used to dictate cellular localization and exert spatiotemporal control
over cues presented to the immune system. As such, scaffolds can be exploited to
enhance the efficacy of cancer immunotherapies such as adoptive T cell transfer, in
which localization and persistence of tumor-specific T cells dictates treatment outcome.
Biomimetic polyisocyanopeptide (PIC) hydrogels are polymeric scaffolds with beneficial
characteristics as they display reversible thermally-induced gelation at temperatures
above 16◦C, which allows for their minimally invasive delivery via injection. Moreover,
incorporation of azide-terminated monomers introduces functional handles that can be
exploited to include immune cell-modulating cues. Here, we explore the potential of
synthetic PIC hydrogels to promote the in vitro expansion and in vivo local delivery of
pre-activated T cells. We found that PIC hydrogels support the survival and vigorous
expansion of pre-stimulated T cells in vitro even at high cell densities, highlighting their
potential as 3D culture systems for efficient expansion of T cells for their adoptive
transfer. In particular, the reversible thermo-sensitive behavior of the PIC scaffolds favors
straightforward recovery of cells. PIC hydrogels that were injected subcutaneously
gelated instantly in vivo, after which a confined 3D structure was formed that remained
localized for at least 4 weeks. Importantly, we noticed no signs of inflammation, indicating
that PIC hydrogels are non-immunogenic. Cells co-delivered with PIC polymers were
encapsulated within the scaffold in vivo. Cells egressed gradually from the PIC gel
and migrated into distant organs. This confirms that PIC hydrogels can be used to
locally deliver cells within a supportive environment. These results demonstrate that PIC
hydrogels are highly promising for both the in vitro expansion and in vivo delivery of
pre-activated T cells. Covalent attachment of biomolecules onto azide-functionalized PIC
polymers provides the opportunity to steer the phenotype, survival or functional response
of the adoptively transferred cells. As such, PIC hydrogels can be used as valuable tools
to improve current adoptive T cell therapy strategies.
Keywords: adoptive T cell transfer, biomaterial-based scaffold, polyisocyanopeptide hydrogel, 3D culture,
injectable, T cells
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INTRODUCTION
Scaffolds produced from a variety of biomaterials are now widely
applied as engineered microenvironments or delivery vehicles
in biomedical applications. These biomaterial-based scaffolds
can be used as three-dimensional (3D) culture systems in vitro
to more faithfully recapitulate the complex set of cues that
cells receive in the body (1). Alternatively, biomaterial-based
scaffolds can be applied in vivo as delivery vehicles of bioactive
molecules or cells, since they can exert spatiotemporal control
over the release of bioactive molecules (2, 3) and dictate cellular
localization (4, 5). Precisely these characteristics can be highly
valuable for the field of immunoengineering to benefit cancer
immunotherapy, as scaffolds can be applied as tools to induce
strong and durable anti-cancer immune responses (6, 7).
Biomaterial-based scaffolds are able to overcome several
limitations associated with current cancer immunotherapeutic
strategies and thereby enhance efficacy and reduce treatment-
related toxicity. For instance, scaffolds have been used for efficient
cancer vaccination by recruiting dendritic cells (DCs) toward a
depot of tumor antigens and adjuvants in the context of a local
3D environment in the body, which obviates the need for time-
intensive ex vivo DC culturing protocols (8–10). Alternatively,
toxicity associated with systemic immune checkpoint blockade
can be reduced by the local and sustained release of anti-
programmed death ligand 1 (PD-L1) and chemotherapy from
scaffolds (11). By acting as molecular and cellular delivery
vehicles with high spatiotemporal resolution, biomaterial-based
scaffolds can have a clear additive value to current cancer
immunotherapeutic strategies.
The ability to control the 3D environment and direct cellular
localization can be especially beneficial to enhance the efficacy
of cellular cancer immunotherapies such as adoptive T cell
transfer (ACT). Adoptive transfer of T lymphocytes is aimed
at eliminating tumor cells by infusing cancer patients with
high numbers of autologous tumor-reactive tumor infiltrating
lymphocytes (TILs). This potent strategy exploits the natural
capacity of cytotoxic T cells to recognize and kill cancerous cells,
and encouraging results have been reported for various solid
cancer types (12–15). However, systemic injection of expanded
tumor-reactive T cells results in insufficient localization of
infused lymphocytes to the tumor site and a lack of in vivo
persistence (16, 17), even though high cell quantities (typically
1010 cells) are administered. Moreover, for many cancer patients
it is not feasible to generate these large amounts of TILs, which
is one of the factors that hampers widespread application of
ACT across different solid cancers types (18). Lymphodepleting
conditioning of the host and co-infusion of high dose bolus
IL-2 are applied to enhance the accumulation and survival
of adoptively transferred cells (19), but both cause significant
wide-spread toxicity (18). Thus, poor T cell persistence and
functionality hamper the clinical efficacy of ACT for solid tumors
(20–24), particularly since the degree of persistence of the
administered lymphocytes is associated with outcome (25, 26).
There is a great medical need to develop more efficient and rapid
approaches for the ex vivo expansion of TILs and to improve
the delivery and persistence of T lymphocytes. These hurdles
can be overcome by making use of biomaterial-based scaffolds as
efficient 3D culture systems and by dictating cellular localization
by exploiting scaffolds as cellular delivery vehicles.
In this study, we explore the potential of an injectable scaffold
to harbor and support the expansion of pre-activated T cells
ex vivo and we studied the feasibility of injecting these gels
in vivo for localized T cell delivery. We present a scaffold
that consists of a polymeric hydrogel that is based on fully-
synthetic tri-ethylene glycol-substituted polyisocyanopeptides
(PIC). Hydrogels generally provide excellent biocompatibility
due to their high water-content which facilitates rapid diffusion
of nutrients and chemical cues. The PIC hydrogels are composed
of a bundled network of synthetic PIC polymers (27), which
have the advantage that they are well-defined and have a
tunable composition. These polymers allow for incorporation of
azide click-handles, which can be used to functionalize the gels
with biomolecules such as integrin-binding motifs (28, 29). In
particular, a unique feature of PIC hydrogels is their biomimetic
strain-stiffening behavior that resembles the mechanical behavior
found in natural polymers, where upon strain the stiffness of the
material increases (27, 30). The PIC polymers display thermally-
induced gelation at temperatures above 16◦C, upon which
they form into a transparent hydrogel (27, 30). This enables
straightforward encapsulation of cells and importantly enables
delivery of these gels in vivo via needle-mediated injection.
The PIC gels can therefore be administered in a minimally
invasivemanner, which diminishes risks of complications that are
associated with implantation of scaffolds.
Here, we demonstrate that PIC hydrogels support the
survival and expansion of ex vivo cultured T lymphocytes. We
furthermore describe the in vivo gelation of PIC polymers after
injection and study its biocompatibility. Collectively, we provide
evidence that PIC hydrogels are highly promising 3D scaffolds for
the in vitro expansion and in vivo delivery of pre-activated T cells
which puts PIC hydrogels forward as valuable tools to improve
current adoptive T cell therapy strategies.
MATERIALS AND METHODS
Preparation of Polyisocyanopeptide
Polymers and Conjugation of GRGDS
Peptide
Non-functionalized and azide-functionalized tri-ethylene
glycol-substituted polyisocyanopeptide (PIC) polymers were
synthesized as previously described (28, 29). Briefly, non-
functionalized isocyano-(D)-alanyl-(L)-alanine monomer and
azide-terminated monomer mixed at a molar ratio of 1:30
were dissolved in toluene. After adding nickel percholate
(Ni(ClO4)2) as a catalyst (catalyst-to-monomer molar ratio of
1:1,000), the reaction mixture was stirred at room temperature
for 72 h. The reaction product was precipitated three times
from dichloromethane in di-isopropyl ether. To produce
GRDGS-functionalized PIC polymers (RGD-PIC), a solution
of DBCO-NHS in DMSO was mixed with GRGDS peptide
dissolved in borate buffer (pH 8.4) at 2 mg/mL and stirred for
3 h at room temperature. Mass spectrometry was performed to
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confirm the formation of DBCO-GRGDS conjugates. DBCO-
GRGDS peptide was conjugated to azide-functionalized PIC
polymers via strain-promoted azide-alkyne cycloaddition at a
ratio of one DBCO-GRGDS per 100 monomers (28). DBCO-
sulfo-Cy5 (Jena Bioscience) at a ratio of one DBCO-sulfo-Cy5
per 5,000 monomers was conjugated to the azide-functionalized
PIC polymers in a similar manner to generate fluorescent PIC
polymers.
Rheological Analysis and Characterization
of PIC Polymers and Hydrogels
RGD-PIC and PIC polymers were dissolved at 3 mg/mL in
X-VIVO-15 medium (Lonza) supplemented with 2% human
serum (HS) by rotation at 4◦C for 24–36 h and dissolved
polymers were stored at −20◦C. Bulk stiffness measurements
on gels was done by rheology analysis at 37◦C were performed
as described (28) using temperature sweep rheology followed
by time sweep experiments. Peripheral blood leukocytes or pan
T cells were incorporated in the gels at a concentration of
0.5 or 1 × 106 cells/mL at gel concentrations of 0.75 and
1.5 mg/mL. PIC polymers were furthermore characterized by
circular dichroism at 0.1 mg/mL in PBS on a Jasco 815CD
spectrophotometer. Atomic force microscopy was performed to
confirm appropriate length and molecular weight (28). In all
functional experiments rheological analysis was performed to
validate proper gel formation and gel bulk stiffness.
Preparation of Collagen Gels
Three-dimensional collagen matrices were prepared at 1.7
mg/mL by mixing 55.5% (v/v) of pepsinized bovine type 1
collagen (3.1 mg/mL, PureCol, Advanced Biomatrix), 3.7% (v/v)
0.75% sodium bicarbonate solution (Life Technologies), 7.4%
(v/v) minimum essential Eagle’s medium (Sigma-Aldrich) and
33.3% (v/v) X-VIVO-15 medium with 2% HS containing cells
at a final concentration of at a concentration of 0.5 or 1 × 106
cells/mL. The matrices (final pH 7.4) were polymerized at 37◦C
for 30–45min.
Cell Isolation, Cell Culture, and Reagents
Human dendritic cells, pan T cells and natural killer (NK)
cells were isolated from buffy coats obtained from healthy
volunteers. This study was carried out in accordance with the
recommendations of institutional guidelines. All subjects gave
written informed consent in accordance with the Declaration
of Helsinki. CD1c+ mDCs were isolated from peripheral blood
mononuclear cells (PBMCs) using the CD1c (BDCA-1) DC
isolation kit. Pan T cells and NK were isolated from peripheral
blood leukocytes using the Pan T cell isolation kit and the
NK cell isolation kit, respectively, according to manufacturer’s
prescription (allMiltenyi Biotec). Cell phenotype was determined
using flowcytometry staining: CD11c (BD Biosciences)/CD1c
(Miltenyi Biotec) for CD1c+ mDCs (purity>85%), CD3
(eBioscience) for pan T cells (purity >98%), CD69 and CD25
(both BD Pharmingen) for T cell activation, CD56 (BD
Biosciences) for NK cells (purity >92%). Human DCs, T cells
andNK cells were cultured inX-VIVO-15medium supplemented
with 2% HS. For NK cell culture an additional 100 IU/mL of IL-2
(Proleukin, Norvartis) was added.
Embedding Cells Within PIC Gels and Cell
Viability
Human pan T cells were activated overnight using plate-
immobilized αCD3 monoclonal antibodies (clone OKT3,
1µg/mL, BioXcell) and αCD28 monoclonal antibodies (clone
9.3, 5µg/mL, BioXcell). Non activated pan T cells, activated pan
T cells, immature DCs or NK cells were incorporated within
(RGD-) PIC hydrogels by mixing cold (RGD-) PIC polymers
with the cells on ice at a final gel concentration of 0.75 or 1.5
mg/mL and a cell concentration of 0.5–1 × 106 cells/ml unless
indicated otherwise. Instantaneous gelation of the RGD-PIC gel
when placed at 37◦C ensured embedding of cells throughout
the 3D matrix. Pan T cells were labeled with PKH-26 (PKH26
Red Fluorescent Cell Linker Kit, Sigma Aldrich) and imaged
on Olympus FV1000 Confocal Laser Scanning Microscope to
test distribution in the gel, and a z-stack reconstruction was
made using FIJI software. For cell viability experiments, cells
were simultaneously encapsulated in collagen scaffolds. After
4, 24, 48, and 72 h, cells were recovered from (RGD-) PIC
gels by incubating the gels at 4◦C for 15–30min, addition of
ice cold PBS and collecting the cell pellet from the fluid after
centrifugation. Cells were retrieved from the collagen scaffolds
by enzymatic digestion for 45min at 37◦C using collagenase
A (Roche). Cell viability was assessed using Annexin V (BD
Pharmingen) and 7AAD staining (eBioscience). Flow cytometric
analysis was performed on a FACS Calibur (BD Biosciences) or
FACS Verse (BD Biosciences) and all data was analyzed using
FlowJo software (Version X 10.0 Tree Star).
Time-Lapse Microscopy and Quantification
of Cell Migration
Migration of individual cells (activated T cells or immature
DCs) encapsulated within (RGD-) PIC hydrogels or collagen
matrices was monitored by digital time-lapse, bright-field inverse
microscopy in a humidified environmental chamber (37◦C and
5% CO2). Images were collected for 4 h at 2.5min time intervals
with a digital CCD camera (Nikon Diaphot 300 with Hamamatsu
C8484-05G CCD Camera, okolab 2D time lapse software).
Migration was quantified by tracking 30 randomly selected cells
for 3 h with manual tracking FIJI software, beginning >30min
after the start of imaging and using the xy coordinates of cell
paths. Cell velocity per cell was calculated as the length of
each cell path divided by time, excluding stop phases. The xy
trajectories were converted into the mean square displacement
(MSD) as previously reported (31). Cells were classified as motile
when they show a MSD of >200 um2 in the first 2 h of cell
tracking. Chemotaxis and Migration Tool software (version 1.01,
Ibidi) was used to plot migration trajectories.
T Cell Proliferation in 3D Matrices
Human pan T cells were stained with CellTrace
TM
CFSE
Cell Proliferation Kit (Invitrogen) to track cell proliferation
by flowcytometry. To pre-activate T cells, pan T cells were
stimulated overnight with αCD3/αCD28 Dynabeads (Gibco).
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The following day, T cells were harvested and re-plated into
two-dimensional (2D) medium, 3D collagen matrices or 3D
RGD-PIC hydrogels at varying cell densities as indicated.
Alternatively, unstimulated T cells (1 × 106 cells/ml) were
mixed with αCD3/αCD28 Dynabeads (Gibco) or with IL-2
(90-100 IU/mL), PHA (phytohaemagglutinin, 1µg/mL, Sigma
Aldrich) and IL-6 (15 ng/mL, Cell Genix). Subsequently, cells
were embedded within the RGD-PIC hydrogels or collagen
matrices at varying densities to test in situ activation. Cells
were recovered from the RGD-PIC gels and collagen gels and
proliferation by CFSE dilution and activation were assessed by
flowcytometry on a FACS Verse (BD Biosciences). Cell numbers
were quantified using a MACSQuant Analyzer 10 (Miltenyi
Biotec). Fixable Viability Dye eFluor R© 780 (eBioscience) was
used to exclude dead cells. Intracellular staining for interferon
gamma (IFNy) was done using anti-IFNy (BD Biosciences) and
the BD Cytofix/Cytoperm Fixation/Permeabilization.
In vivo PIC Gel Stability and Adoptive
Transfer of Pre-Stimulated T Cells
Mice were housed at the Central Animal Laboratory (Nijmegen,
the Netherlands) where food and water were provided ad libitum.
This study was carried out in accordance with European
legislation. The protocol was approved by the local authorities
(CCD, The Hague, the Netherlands) for the care and use of
animals with related codes of practice. Animals were randomly
allocated to groups. To pre-activate T cells ex vivo before adoptive
transfer, mouse pan T cells [mouse pan T cell isolation kit
(Miltenyi Biotec)] were isolated from the spleens and inguinal
lymph nodes of wild-type female C57BL/6J mice (age 5–8
weeks, Charles River) congenic for the CD45.1 marker. T cells
were stained with CellTrace
TM
CFSE and activated for 16 h
with immobilized αCD3 monoclonal antibodies (1 ug/mL, clone
17A2, Cell Genix) and αCD28 monoclonal antibodies(2 ug/mL,
clone 37.51, Cell Genix). Cell phenotype was determined using
flowcytometry staining: CD3 (purity typically >98%), CD69 and
CD25 (all Biolegend). Azide-functionalized PIC polymers were
dissolved in phenol-red free RPMI medium and were confirmed
to be endotoxin free using the LAL test (Lonza). Rheology was
performed to confirm adequate gel stiffness. PIC polymers were
labeled for 2 h with DCBO-sulfo-Cy5 (Jena Bioscience) and for
some experiments with 250 IU/mL IL-2 for 4 h at 4◦C. Next,
pre-activated CFSE-labeled CD45.1+ T cells were mixed with the
PIC polymers or with phenol-red free RPMI medium (control),
at a final concentration of 1.5 × 106 cells/100 µl. Rheology
confirmed that this number of cells did not significantly affect
PIC gel stiffness.When IL-2 was attached onto PIC polymers, 250
IU/mL IL-2 was added to the control as well. The PIC polymers
were kept on ice and injected s.c. under anesthesia into the
dorsal flank of female C57BL/6J mice congenic for the CD45.2
marker (age 5–8 weeks; Charles River, housed at 28◦C) in order
to discriminate the adoptively transferred T cells from host T cells
by flowcytometry. Fluorescent images were collected with the
IVIS Lumina imaging system (Cy5 signal: 640 nm, Cy5.5 filter,
CFSE signal: 465 nm, GFP filter, Perkin Elmer) after 2 h, 1, 3,
7, 14, 21, or 28 days to investigate gel localization and cellular
localization. At designated time points, gels were excised from the
dorsal flank and the remaining PIC gel, blood, spleen, draining
and non-draining lymph nodes (LNs) were collected. Single cells
suspension were made from the excised gels, spleen and LNs by
digestion with DNAse (20µg/mL, Roche) /collagenase type III
(1 mg/mL, Worthington) and from the PIC gels by cooling and
DNAse/collagenase treatment. The percentage, proliferation and
phenotype of CFSE-labeled CD45.1+ T cells were quantified by
flow cytometry. All flow cytometric analysis was performed on
a FACS Verse. A TNF-α ELISA (eBioscience) was performed on
serum collected on day 1.
Immunohistochemistry
On various time points after s.c. injection of Cy5-labeled PIC
gels with T cells, PIC gels were resected from the dorsal flank
of the mice. The tissues were fixed overnight in 4% PFA at RT.
Tissues were embedded in paraffin and 10 um FFPE sections
were cut. Antigen retrieval was performed using citrate pH
6.0 (Scytek). Slides were stained with primary anti-CD3 (1:300,
clone CD3-12, #MCA 12477, Serotec) and secondary rabbit-
anti rat HRP (1:100, Jackson Immunoresearch). Tyramide signal
amplicification visualization was performed with the Opal seven-
color IHC Kit according to protocol (PerkinElmer) containing
fluorophores DAPI and Opal 540. Slides were mounted using
Fluormount without DAPI (SouthernBiotech) and scanned
using the PerkinElmer Vectra (Vectra 3.0.5; PerkinElmer).
Multispectral images were unmixed using spectral libraries using
the inForm Advanced Image Analysis software (inForm 2.2.1;
PerkinElmer) and analysis was performed by applying an inForm
software algorithm (tissue segmentation, cell segmentation,
phenotyping tool, and positivity score) based on training with on
a selection of 10 representative original multispectral images.
Statistical Analysis
Statistical analyses were performed inGraphPad Prism 5 software
using the appropriate testing methods, as indicated in the
figure legends. Statistical significance was defined as a two-sided
significance level of <0.05. ns= not significant, ∗p ≤ 0.05, ∗∗p ≤
0.01, ∗∗∗p ≤ 0.001, ∗∗∗∗p ≤ 0.0001.
RESULTS
Characterization of Thermoresponsive
Polyisocyanopeptide Hydrogels
We produced thermoresponsive hydrogels from tri-ethylene
glycol-substituted polyisocyanopeptides (PIC). Methoxy-
terminated and azide-terminated isocyanide monomers
were co-polymerized with a nickel perchlorate (Ni(ClO4)2)
catalyst in a molar ratio of 1:30 to create azide-containing
PIC polymers (Figure 1A). These fully synthetic PIC polymers
have an average of one azide functionality every ∼3 nm of
the polymer chain (28). In order to construct cell-adhesive
polymers that would promote interaction of cellular integrin
receptors with the matrix, RGD peptide ligands were grafted
onto the azide-functionalized PIC polymers via strain-
promoted cycloaddition at a ratio of one DBCO-GRGDS
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FIGURE 1 | Tri(ethylene glycol)-substituted polyisocyanopeptides (PIC) form soft thermoresponsive gels that can be functionalized via the azide-terminated tail.
(A) Molecular structure of polyisocyanopeptides substituted with tri(ethylene glycols) and azide functionalization. Azide-functionalized monomer (top) and
unfunctionalized monomer (bottom) are co-polymerized in a 1:30 ratio. (B) Representative rheological analysis of PIC polymers at 1.5 mg/mL without cells, where G
′
as a measure of bulk stiffness is set out against temperature. The material gelates at the LCST of 16◦C. (C) Z-stack reconstruction of confocal imaging of PKH-26
labeled T cells within PIC hydrogel at 1.5 mg/mL. (D) G
′
value as a measure of bulk stiffness of PIC hydrogel and RGD-PIC gels, determined with rheological analysis
at 37◦C. Between 0.5 × 106 and1 × 106 cells/mL were incorporated into the gels. Values represent mean and standard error of the mean (SEM). Data were analyzed
with the Kruskal Wallis test and the Dunns post-test. n = 3–10 in at least three independent experiments. *p ≤ 0.05, **p ≤ 0.01.
per 100 monomers. We analyzed PIC polymers and GRGDS-
functionalized PIC polymers (RGD-PIC) by rheology to
investigate their bulk stiffness. The polymers demonstrated
instantaneous temperature-dependent gelation with an
average lower critical solution temperature (LCST) of 16◦C
(Figure 1B), resulting in the formation of transparent hydrogels
at temperatures above the LCST. These thermoresponsive
characteristics and gelation temperature are key to warrant
straightforward cell encapsulation and injectability of the
material.
Next, we mixed primary T cells with cold PIC and RGD-
PIC polymer solutions at 4◦C and warmed them to 37◦C
to encapsulate cells during gel formation. As gelation of the
PIC polymers occurs virtually instantaneous (within 1min)
upon warming of the polymer solution, cells were encapsulated
homogenously in a genuine 3D fashion within the nanoporous
network of bundles (Figure 1C). We performed time sweep
rheological analysis to measure bulk stiffness of different batches
of PIC gel and RGD-PIC polymers, either empty or after
encapsulating cells, to investigate the effect of encapsulating
adhesion motifs and cells on the material properties. As
anticipated, rheology measurements indicated that PIC and
RGD-PIC hydrogels exhibit a concentration-dependent stiffness
and form soft gels with a stiffness ranging between 0.03 and
0.4 kPa (Figure 1D). The presence of RGD within the hydrogels
reduced the average bulk stiffness of the gels, especially for PIC
gels with higher stiffness. The incorporation of cells did not affect
stiffness significantly at a density of 0.5–1 × 106 cells/mL of
gel.
Polyisocyanopeptide Hydrogels Are
Biocompatible and Sequester T Cells
To establish whether PIC and RGD-PIC hydrogels are
biocompatible and can promote the survival of primary T
cells, we embedded pre-stimulated primary human T cells
within (RGD-) PIC gels and cultured them at 37◦C. Due to
the thermoreversible behavior of the hydrogels, cells could
be easily retrieved from the 3D matrices for phenotypical
analysis by incubating the gels at 4◦C. Primary T cells remained
highly viable within PIC and RGD-PIC hydrogels for at
least 3 days at levels comparable to that in medium and
collagen type I hydrogels (Figure 2A). The wide applicability
of PIC hydrogels is further supported by the notion that
primary human dendritic cells (DCs) and primary natural
killer (NK) cells are also viable within the PIC hydrogels
at a similar level as cells cultured in medium or collagen
(Supplementary Figures 1A,B), demonstrating that PIC
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FIGURE 2 | PIC hydrogels support T cell survival and restrict T cell migration within the matrix. (A) Viability of αCD3/αCD28 dynabead-activated T cells in medium,
collagen gels, and (RGD-) PIC hydrogels, defined as the percentage of 7AAD−Annexin V− cells. n = 3 in one experiment. (B) Top: Representative images of 3 h cell
tracks of individual activated T cells in collagen gels and PIC hydrogels. Each dot and/or track represents one randomly chosen cell out of 30. Bottom: Trajectories of
30 individual activated T cells from one representative experiment. (C) The percentage of motile cells relative to the number of motile cells in collagen. Cells are
(Continued)
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FIGURE 2 | classified as motile when they show a mean squared displacement (MSD) of >200 um2 in the first 2 h of cell tracking. (D,E) The average velocity depicted
for the average of all cells (D) or per single cell (E) based on tracking of 30 randomly chosen cells for 3 h in collagen gels and (RGD-) PIC hydrogels. (F) The mean
squared displacement of 30 cell tracks in collagen and (RGD-) PIC hydrogels that were tracked for 2 h. (A,C–F) Values represent mean and SEM. (C–E) Data were
analyzed with the Kruskal Wallis test and the Dunns post-test. (F) A two-way ANOVA with a Bonferroni post-test was performed to test for statistical significance.
(C–F) n = 6 for collagen and PIC gel 0.75 mg/mL and n = 3 for others in at least three independent experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
hydrogels support 3D cell culture of a wide variety of primary
immune cells.
The 3D matrix that is formed by the bundles of the
PIC polymers consist of a tight nanoporous network with an
estimated average pore size of 200 nm, which is physically
crosslinked by bundling of polymer chains at temperatures
above the LCST (27). We aimed to characterize the migratory
behavior of immune cells within PIC hydrogels to understand
how immune cells behave in this 3D culture system. We tracked
non-directional migration of pre-activated T cells in PIC and
RGD-PIC hydrogels within 4 h after their encapsulation, and
compared it to random migration in collagen type I hydrogels
with pore diameters of 2–6 um as a mimic of a natural
3D matrix that supports immune cell migration (32). Time-
lapse microscopy revealed that primary T cells hardly migrate
through PIC hydrogels, in contrary to T cells encapsulated
in collagen gels (Figures 2B–F). The ability to migrate was
directly dependent on gel concentration as increasing PIC gel
concentration to 1.5 mg/mL completely arrested cell migration,
possibly as a result of enhanced gel stiffness (Figure 1D). A
minor decrease in pore size could contribute to this as well
as pore size correlates inversely with polymer concentration
(27). Next, we investigated whether functionalizing PIC gels
with RGD integrin-binding motifs would promote T cell
migration. RGD peptide ligands interact with α4β1 integrins
on T cells (33) and are frequently incorporated into synthetic
biomaterials in order to promote cellular adhesion and enhance
interaction of cells with biomaterials (34). T cells did not
display increased migration through gels bearing RGD adhesion-
motifs compared to non-functionalized gels, even though RGD-
PIC hydrogels generally have a lower bulk stiffness than PIC
gels (Figures 2B–F). This could suggest that the compact
bundled network of the PIC hydrogels is the main determining
factor of cellular migration. Alternatively, it could also be a
result predominantly integrin-independent amoeboid migratory
behavior that T cells utilize (35), which is therefore not
enhanced by the presence of integrin-binding motifs. Tracking
random migration of immature myeloid DCs demonstrated
that they displayed migratory behavior similar to that of
T lymphocytes within PIC gels, as they were restricted in
their migration through the tight network with small pores
(Supplementary Figures 1C–F). However, DCs retained higher
levels of migration compared to T cells in 0.75 mg/mL PIC
hydrogels, probably because of differences in their ability to
deform their nucleus as this is one of the determining factors
when physical restrictions are imposed on migration (32). The
finding that DCs preserve some of their migratory capacity
within the PIC matrix implies that the polymer network does
not inhibit the intrinsic migratory function of cells but instead
poses a physical barrier. These observations together with
the notion that immune cells are viable within (RGD-) PIC
gels (Figure 2A, Supplementary Figures 1A,B) suggest that cell
migration is restricted because of physical restraints imposed by
the PIC polymer bundles which sequesters cells within the 3D
matrix.
Next, we studied whether the absence of immune cell
migration in PIC gels affects their inherent capacity to become
activated by stimulatory cues. Activation and proliferation
of primary T cells embedded in RGD-PIC hydrogels could
be induced by introducing T cell-activating αCD3/αCD28
dynabeads, but only when relatively high numbers of cells and
high numbers of beads were mixed together which statistically
enhances the chance of a T cell-activating bead and a non-
migratory T cell to interact (Supplementary Figures 2A–C).
This shows that sequestered T cells still have the potential
to become activated and expand. Moreover, these T cells
can also be activated using soluble T cell activators such as
PHA/IL-6/IL-2 (Supplementary Figure 2D), further confirming
that the inherent capacity of encapsulated cells for activation and
proliferation is not affected by the dense RGD-PIC gel matrix.
Collectively, these data show that PIC and RGD-PIC
hydrogels are biocompatible matrices that can be used to culture
primary T cells and other primary immune cells in a 3D
environment. The dense polymer network physically restricts
immune cell migration but does not affect T cell ability to become
activated or expand.
Primary T Cells Can be Expanded at High
Cell Densities Within PIC Hydrogels
In adoptive T cell therapy approaches such as TIL therapy, T
cells need to be expanded to high numbers of tumor-reactive
T cells as typically 1010 cells are administered to patients
(36). Therefore, we tested if PIC hydrogels could facilitate and
promote the proliferation of pre-activated T cells embedded
within the 3D scaffold. We incorporated human pan T cells
into PIC hydrogels functionalized with RGD to support integrin-
mediated T cell interaction with the matrix. Non-activated T
cells cultured with RGD-PIC hydrogels did not proliferate,
demonstrating that RGD-PIC scaffolds do not intrinsically
induce T cell expansion (Supplementary Figure 3A). Next,
we activated T cells with αCD3/αCD28-coated dynabeads
(Supplementary Figure 3B) and transferred these pre-activated
T cells into 2D medium, collagen gels or RGD-PIC hydrogels
at a density of 1 × 106 cells/mL and studied their proliferation.
Pre-activated lymphocytes expanded rapidly and extensively in
RGD-PIC gels similar to that of T lymphocytes embedded
in collagen gels or in 2D medium, with proliferation rates
ranging from 60 to 80% (Figures 3A–C, low cell density). We
hypothesized that the 3D environment provided by the RGD-
PIC gels could be beneficial for expansion of T cells at high
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FIGURE 3 | Pre-stimulated T cells display extensive proliferation within RGD-PIC hydrogels, even at high cell densities. (A) Representative histograms of
CFSE-labeled pre-activated pan T cells cultured in medium, collagen gels or RGD-PIC gels (1.5 mg/mL) for 3 days. Low cell density: 1 × 106 cells/mL, medium cell
density: 2.5 × 106 cells/mL, high cell density: 5 × 106 cells/mL. (B–D) The percentage of proliferated T cells defined as cells that have undergone at least 1
proliferation cycle (B), the proliferation index defined as the number of cycles of proliferating T cells (C) and a quantification of the absolute number of cell retrieved
(D) 72 h after transferring pre-activated T cells to medium, collagen or RGD-PIC gels at varying cell densities. Low cell density: 1 × 106 cells/mL, medium cell density:
2.5 × 106 cells/mL, high cell density: 5 × 106 cells/mL. (B–D) Values represent mean and SEM. Data were analyzed with the Kruskal Wallis test and the Dunns
post-test. n = 2 or 3 in at least two independent experiments. *p ≤ 0.05.
quantities and therefore we increased the density of T cells
within the gels with 2.5 times (“medium cell density”) and 5
times (“high cell density”). Notably, T lymphocytes propagated
extensively in RGD-PIC gels and collagen gels at high cell
densities, in contrast to T cells cultured in 2D in medium where
cellular crowding inhibited T cell expansion (Figures 3A–C).
Quantification of the number of T cells demonstrated that
significantly more T cells could be retrieved from RGD-PIC gels
compared to T cells cultured in 2D medium when they were
cultured at high cell densities (Figure 3D). On the contrary, at
low cell densities most cells were retreived from 2D medium
cultures, eventhough T cell proliferated at similar speed in
collagen and RDG-PIC gels. This indicates that cells are lost
during cell recovery, which might be caused by collagenase
treatment required to retrieve cells from collagen. For RGD-PIC
gels, this is probably the result of a higher viscosity compared
to medium, indicating that optimizaton of the cell retrieval
process could further increase the number of T cells that can
be obtained. The percentage of IFNy-producing T cells in RGD-
PIC gels was comparable to that of T cells expanded in collagen
and medium (Supplementary Figure 3C), again suggesting that
RGD-PIC gels do not inhibit T cell functions including cytokine
production. These data confirm that the RGD-PIC hydrogels
are able to support the propagation of T cells and can promote
the rapid proliferation of pre-stimulated T cells at high cell
densities.
Polyisocyanopeptide Polymers Form
Stable Gels in vivo and Are
Non-immunogenic
After having established that PIC gels support the survival and
proliferation of T cells as 3D culture systems in vitro, we wanted
to explore the feasibility of applying PIC gels in vivo. One of
the key advantages of the thermoresponsive properties of PIC
hydrogels is the opportunity to introduce these into the body in
a minimally invasive manner via in vivo gelation after needle-
mediated injection of a cold PIC polymer solution, as opposed
to pre-formed scaffolds that require implantation. We set out
to explore the potential of PIC hydrogels for the subcutaneous
(s.c.) delivery of immune cells via injection in order to deliver
high numbers of cells concentrated in a relatively small volume
into the tissue, whilst retaining the effector functions of the
expanded T cells (Figure 3C, Supplementary Figure 3C). The
PIC gel could in this way be used to dictate cellular localization
and at the same time provide a supportive matrix that promotes
cellular proliferation.
To investigate the gelation of cold PIC polymers in vivo
after subcutaneous injection, we labeled azide-functionalized
PIC polymers with DBCO-sulfo-Cy5. We injected 100 µl
of cold 1.5 mg/mL PIC polymers mixed with pan T cells
suspended in medium s.c. into the dorsal flank of C57Bl/6J
mice. Fluorescent imaging starting 2 h after injection (day 0)
revealed that a confined structure was formed (Figure 4A),
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suggesting that gelation in vivo occurs rapidly before polymers
get dispersed over the subcutaneous space. The PIC gel
remained localized in the dorsal flank for at least 4 weeks
and significantly decreased in fluorescence intensity after 4
weeks (Figures 4A,B), which could suggest that the gel is
degrading over time and washed away from the injection
site when gel stability reaches a lower limit. Importantly,
mice did not show any signs of distress nor weight loss
during the entire 4 weeks after gel administration, indicating
that PIC gels are well tolerated. To study whether the
PIC gel induces inflammation, we resected the PIC gels
and the surrounding tissue to compare the presence of
neutrophils and macrophages to that of a similar sized piece
of skin close to the injection site of control mice injected
with T cells in medium without PIC polymers. PIC gels
did not induce any recruitment or influx of inflammatory
neutrophils or macrophages toward or into the PIC gels
compared to control mice (Figures 4C,D), indicating that the
scaffolds are non-immunogenic. This was confirmed by the
observation that predominantly CD11b+CD11c− macrophages
and CD11b+CD11c+ myeloid DCs take up some of the Cy5-
labeled PIC polymers (Figure 4E) but these Cy5+ DCs do
not migrate toward the draining lymph nodes of these mice
(Figure 4F), suggesting that DCs do not receive any activation
cues as a result of polymer uptake. Moreover, we did not
detect any differences in the serum levels of TNFα 1 day
after injection between mice injected with PIC gels vs. mice
injected with medium (Figure 4G). Thus, s.c. injection of PIC
polymers together with T lymphocytes results in the formation
of a stable PIC gel without induction of local or systemic
immune activation. This suggests that PIC hydrogels are non-
immunogenic, biocompatible and can be safely used for in vivo
immunomodulation.
Pre-activated T Cells Delivered via PIC
Gels Maintain Their Function and Are
Slowly Released Into the Environment
Next, we investigated whether T cells could be encapsulated
within PIC gels after s.c. injection and in vivo gelation. We mixed
1.5× 106 CFSE-labeled pre-stimulated primarymouse T cells per
100 µl of cold Cy5-labeled PIC polymers. After s.c. injection, we
could see a clear colocalization of the Cy5 signal coming from the
PIC gel together with the CFSE signal from the T lymphocytes
(Figure 5A). We resected the PIC gels on various time points
after injection and performed immunohistochemistry for CD3
to localize and quantify the number of CD3+ T cells within the
gel. T cells could be identified as high-density clusters within
the polymers of the PIC hydrogel and localized mainly within
or in close proximity to the gel (Figure 5B), confirming that T
cells are encapsulated within PIC gels after in vivo gelation. This
implies that T cells can tightly interact with the PIC polymers
after co-delivery. Multispectral image analysis through different
sections at varying heights of the PIC gel revealed that the scaffold
contains a relatively consistent number of T cells throughout
the entire gel construct (Figure 5C). Immunohistochemistry
indicated that 1 day after injection there was an average of
more than 4000 CD3+ T cells per mm2 PIC gel. Over time,
the number of T cells within PIC gels gradually diminished
(Figure 5D).
In order to use PIC gels as cellular delivery vehicles of T
lymphocytes for applications such as ACT, it is crucial that
pre-activated T cells retain their proliferative capacity and
functionality after administration while preserving their ability
to move out of the scaffold into the environment. In particular,
we were interested in the release kinetics of T lymphocytes
co-delivered with PIC polymers, as we observed that PIC gels
restrict T cell migration in vitro. To this end, we mixed pre-
activated mouse T cells (CD45.1+) with cold PIC polymer and
adoptively transferred these by s.c. injection in the dorsal flank of
CD45.2+ mice, and compared it to injection of T cells without
PIC gel (Figure 5E). We studied T cell migration away from
the injection site by investigating the presence of CD45.1+ cells
in the spleen, draining lymph node (dLN), non-draining lymph
node (ndLN) and blood at various time points. The relative
amount of CD45.1+ T cells in the PIC gel determined by
flowcytometry decreased starting from day 1 after injection until
day 28 (Figure 5F), confirming data obtained by CD3+ staining
of PIC gel sections (Figure 5D). A decrease of T cells within PIC
gels was accompanied by an accumulation of CD45.1+ T cells
in the dLN at day 3 after injection (Figure 5G). Subsequently,
we detected a steady increase of adoptively transferred T cells
in the non-draining LN, spleen and blood of the recipient mice
up to 4 weeks after injection (Figure 5H). Strikingly, the release
kinetics for T cells mixed with PIC polymers vs. T cells alone was
similar. This suggests that T cells can readily migrate out of the
PIC gels even though they are clustered within the scaffold 1 day
after injection (Figure 5B), and they demonstrated a significantly
restricted cellular migration in vitro on the short term (Figure 2).
The release of T cells from PIC gels in vivo is likely a result of a
decrease in gel stability and finally degradation over time. Thus,
PIC gels incorporate T cells after in vivo gelation and allow egress
of T lymphocytes from the injection site in vivo.
Finally, we performed a detailed characterization of the
phenotype and function of adoptively transferred CD45.1+ T
cells alone or in the context of PIC gels. The PIC gels did
not affect the proliferative capacity (Supplementary Figure 4A)
or the effector/memory phenotype balance of transferred T
lymphocytes (Supplementary Figures 4B,C). Moreover, PD-1
expression on these cells was not changed compared to T cells
injected without PIC gel (Supplementary Figure 4D). Together,
these results suggest that the PIC gel does not negatively
impact the quantity, release kinetics or quality of transferred T
lymphocytes after s.c. delivery.
DISCUSSION
The use of biomaterial-based scaffolds as 3D culture systems and
cellular delivery vehicles is a promising approach to improve
the efficacy of immunotherapy for cancer and reduce toxicity.
Scaffold properties need to be selected and tested systematically
to match these to future applications. Here, we characterize
the potential of PIC hydrogels as 3D culture systems for
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FIGURE 4 | PIC gels form stable gels in vivo that do not cause inflammation. (A,B) Representative example (A) and quantification (B) of the radiant efficiency of IVIS
imaging of mice s.c. injected with 100 µl Cy5-labeled 1.5 mg/mL PIC polymers mixed with T cells in the dorsal flank. N = 6–20 in three independent experiments.
(C,D) The percentage of SSChighLy6G+ neutrophils (D) and CD11b+CD11c− macrophages (E) of all alive CD45.2+ cells that where surrounding or inside the PIC
gel, compared to a similar region of skin in mice injected with medium and T cells. N = 7–9 in at least 3 independent experiments. (E) The percentage of Cy5+ cells of
(Continued)
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FIGURE 4 | the respective subset surrounding or inside the PIC gel of mice injected with Cy5-labeled PIC gel. n = 7–9 in at least 3 independent experiments. (F) The
percentage of Cy5+ cells of all CD11c+CD11b+ DCs in the non-draining lymph node (ndLN) and draining lymph node (dLN) on day 7. n = 4 in 1 independent
experiment. (G) The level of TNFα in serum 1 day after injecting mice with Cy5-labeled PIC polymers or medium mixed with T cells. (B–G) Values represent mean and
SEM. (B) Data were analyzed with the Kruskal Wallis test and the Dunns post-test. **p ≤ 0.01 (C–E) Data were analyzed with the a two-way ANOVA and Bonferroni
post-test. (G) Data were analyzed with the Mann Whitney test. ns, not significant.
primary T cells. We report that PIC gels support expansion
of pre-stimulated T lymphocytes at high cell densities without
affecting cell functionality, in contrast to less physiologically
relevant 2D culture systems where crowdingmay hamper cellular
proliferation (37). This demonstrates that PIC hydrogels are
attractive 3D scaffolds to propagate pre-stimulated T cells to
benefit T cell expansion protocols for ACT, as it can support
extensive T cell expansion in a small volume while preserving
T cell function. As such, we hypothesize that PIC hydrogels
can be used to enhance efficiency of current T cell expansion
protocols and that they could reduce the length of the in vitro
culture period that precedes re-administration of tumor-reactive
T cells, which positively affects the quality of the T cell infusion
product (38, 39). The thermoreversible behavior of PIC hydrogels
facilitates straight forward cell encapsulation into the 3D matrix
and importantly, allows for rapid retrieval of cells. This is a
great benefit over many other 3D culture systems where typically
mechanical or enzymatic disruption is required to retrieve cells,
which can affect cell survival, cell surface markers, phenotype or
gene expression (40).
The mechanical properties of scaffolds are of high importance
for stability during cell culture and may affect cellular behavior.
We establish that the dense bundled network of PIC gels restricts
primary T cell and DC migration, which is not mitigated
by incorporating integrin-binding RGD motifs. This is likely
caused by the physical restraints imposed on encapsulated cells
by the tight bundled network with 200 nm pores (27). T cell
sequestration does not affect their ability to become activated or
proliferate, but has implications on how PIC gels can be applied
as cells cannot freely interact with immobilized activating cues
incorporated into the system. To fully apprehend the potential
of PIC gels as 3D cell culture systems for various cell types, the
precise relationship between gel stiffness, polymer concentration,
the presence of adhesive ligands and migration propensity needs
to be established and specified per cell subtype. It is important to
take into account how gel stability and stiffness change over time,
as prolonged use of PIC gels in 3D cell culture will decrease gel
stiffness and permit cellular migration (41).
We exploit the thermosensitive behavior of PIC polymers to
trigger gelation into 3D matrixes. This is highly advantageous
as gelation occurs under physiological circumstances and does
not require any crosslinkers, organic solvents or potentially toxic
agents to induce gel formation (42, 43). The tri-ethylene glycol-
substituted PIC polymers used in this study have a LCST of
16◦C, which ensures stable gels at physiological temperatures
of 37◦C as gels become more stiff at higher temperatures (27).
A consequence of this LCST is that polymer solutions need to
be kept cool below 16◦C during the handling time and prior
to injection. The LCST of these PIC polymers can be tuned
for instance by the addition of salts (44), but this requires
careful optimization as changing the LCST will also affect
gel stiffness and stability at 37◦C. Thermally-induced gelation
permits minimally invasive delivery in vivo via needle-mediated
injection which precludes the need for a surgical procedure
for scaffold implantation. Injected cold PIC polymers are well
tolerated, form stable gels after in vivo gelation and notably do
not induce a local or systemic inflammatory response, suggesting
that these polymers can be safely used in vivo. In particular,
we observe no neutrophil or macrophage recruitment toward
the gel, which is an important indicator for a lack of scaffold
immunogenicity and a crucial factor for biocompatibility (45–
48). The mode of delivery and precise scaffold formulation
is central in this context, as implantation of RGD-PIC gels
within silicon molds has previously been found to induce
mild granulocyte recruitment (41). This results from a tissue
damage response following implantation together with immune
activation due to RGD peptide ligands immobilized onto the
polymers (49, 50). Moreover, we observe that local in vivo gel
fluorescence diminishes after 4 weeks, which implies PIC gel
degradation and is favorable with respect to biocompatibility.
Degradation is presumably a result of disruption of the non-
covalent interactions that hold the PIC polymer bundles together,
until the hydrogel is too weak to stay intact and is cleared from
the subcutaneous space. Thus, our findings demonstrate that
PIC polymers can be safely used in vivo and can efficiently be
delivered via injection.
By mixing pre-activated T cells with PIC polymers, we could
locally deliver high numbers of T cells in vivo within PIC
gels. T cells move toward distant organs from PIC gels at a
speed similar to that of T cells injected without scaffold, even
though we observed restricted T cell migration in vitro. This
can be explained by distinct gelation behavior after in vitro
vs. in vivo gel formation (51, 52), as tissue pressure and
fluid drainage may affect polymer gelation in vivo. Another
factor is probably weakening of PIC gels over time, causing
T cells to egress out of the scaffolds (41). T cells circulate
systemically and move into distant organs, while preserving
their proliferative capacity and functionality. This is critical to
ensure that PIC-delivered T cells can migrate toward target
sites and execute their (effector) functions. We demonstrate that
cells are in close proximity of PIC polymers after injection and
are migratory, suggesting that extensive cell-matrix interaction
is possible. This provides the opportunity to exploit the azide
handles present on PIC polymers using bio-orthogonal click
chemistry to co-deliver a wide variety of biomolecules that can
steer T cell survival, phenotype or function after administration.
Covalent attachment of T cell survival factors or activating
cues onto the polymers promotes sustained availability of these
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FIGURE 5 | T cells are encapsulated within PIC gels after in vivo gelation and are released into the blood and distant organs. (A) Representative IVIS fluorescent
images of the radiant efficiency of a mouse injected s.c. with 100 ul Cy5-labeled 1.5 mg/mL PIC gel mixed with CFSE-labeled pan T cells in the dorsal flank.
(B) Representative image of a 10µm section of FFPE-treated PIC gel in the skin 1 day after injection. Scale bar = 400 um. (C) Representative quantification of the
number of CD3+ T cells per mm2 PIC gel of 10 um sections through the PIC gel with typically 20–30 um in between each section (1 day after injection).
(Continued)
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FIGURE 5 | (D) Quantification of the average number of CD3+ T cells per mm2 PIC gel of 10 um sections through the PIC gel (n = 2 or 3 per timepoint in 2
independent experiments). Data analyzed with Kruskal Wallis test with dunn’s post test relative to day 1, *p ≤ 0.05. (E) Setup of experiment to study release of T cells
from PIC gels after injection. (F) Quantification of the percentage of CD45.1+ cells of all CD3+ T cells retrieved from PIC gels and surrounding skin. n = 5–7 in at least
3 independent experiments for timepoints day 1–21, n = 2 in 1 independent experiment for day 28. Data analyzed with Kruskal Wallis test with dunn’s post test
relative to day 1, not significant. (G) Representative flow cytometry plot demonstrating CD45.1+ cells gated on CD3 expression in the draining lymph node (LN) on
day 3 after injection of PIC gel with CD45.1+ T cells. (H) Quantification of the percentage of CD45.1+ cells of all CD3+ T cells in the draining lymph node (LN),
non-draining lymph node, spleen and blood. n = 7–9 in at least three independent experiments for timepoints day 1–21, n = 6 in one independent experiment for
timepoint day 28. (D,F,H) Values represent mean and SEM.
factors at a localized area, in contrast to rapid diffusion of
biomolecules administered in a soluble fashion. We hypothesize
that the introduction of T cell-stimulating cues in the PIC
hydrogels may contribute to promoting T cell viability and
functionality in order to outperform T cell delivery through
bolus injection. This can be exploited by introducing IL-2 or
IL-15 agonists into the PIC gels that may locally enhance T
cell viability and persistence (18, 53), while circumventing the
toxicity associated with high dose bolus IL-2 (24). Alternatively,
scaffolds bearing T cell-activating cues such as agonistic CD3
and CD28 antibodies (54) alone or together with αCD137 and
IL-15 agonists (55) can be used to promote vigorous in situ T
cell expansion and improve functionality. Anti-tumor immune
responses can be further boosted by presenting stimulator of
interferon genes (STING) agonists (56). These strategies are
promising to increase efficacy of ACT by locally stimulating and
expanding adoptively transferred T lymphocytes in a tunable 3D
environment compared to conventional bolus injection of pre-
stimulated T cells (55, 56). In addition, this may reduce the need
to support T cell engraftment using toxic co-treatments such as
lymphodepleting chemotherapy and IL-2 (18).
As we describe that PIC hydrogels are not only suitable for
cell culture of primary T cells but also support DC survival
to a similar extent as medium, we speculate that PIC gels
may be suitable for the localized delivery and local stimulation
of DCs for DC-based cancer vaccination approaches. In this
setting DC-stimulating cues such as covalently attached TLR
ligands and tumor antigens can be grafted onto the polymers to
create an immunostimulatory niche (10, 57, 58), although careful
consideration with respect to the local persistence of TLR ligands
and tumor antigens is pivotal to induce anti-cancer immunity
rather than tolerance (59).
Our findings build on previous work that reported that PIC
gels are biocompatible and can support the culture of various cell
types including mesenchymal stem cells, adipocytes, melanoma
cells, fibroblasts and endothelial cells (28, 41). This highlights the
biocompatible nature of PIC hydrogels and puts them forward as
versatile scaffolds that are immunologically silent. Their synthetic
nature and azide-handles create a flexible and controlled platform
that is readily applied for immunomodulation, both in vitro
and in vivo. As such, PIC hydrogels are highly valuable tools as
3D cell culture systems and cellular delivery vehicles, for which
the choice and formulation need to be tailored to the desired
application.
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